

Ad hoc announcement
Inside information pursuant to Article 17 MAR

Partner Magenta Therapeutics Exercises Option to Further Develop Antibody Targeted Amanitin Conjugates Targeted to CD45

Ladenburg, Germany, 11 November 2019 – Heidelberg Pharma AG (FSE: WL6) today announced that its partner Magenta Therapeutics (NASDAQ: MGTA), Cambridge, MA, USA, (Magenta) today declared that it will exercise the option for the exclusive worldwide development and marketing rights for Antibody Targeted Amanitin Conjugates (ATACs) targeting CD45. Heidelberg Pharma receives an undisclosed milestone payment in return. Under Heidelberg Pharma's collaboration with Magenta, Heidelberg Pharma is entitled to receive development and sales-related milestone payments of USD 85m per selected target. Pending successful completion of the research phase, Magenta may begin developing ATACs that target CD45.

In March 2018, both companies signed an exclusive multi-target research agreement under which Magenta gained access to Heidelberg Pharma's Amanitin toxin-linker platform technology. Magenta may apply Heidelberg Pharma's proprietary ATAC technology to up to four exclusive targets from its antibody portfolio to produce novel ATACs. Magenta exercised its first option for the CD117 target in October 2018.

+++ End of the ad hoc announcement +++

About the target molecule

The target CD45 is a surface protein expressed by immune cells and hematopoietic stem cells. An ATAC for CD45 could provide a one-time curative therapy for patients with autoimmune diseases by removing the disease-causing cells, resetting the immune system and allowing the body to rebuild a healthy new immune system.

About Heidelberg Pharma

Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.

Former clinical assets MESUPRON® and REDECTANE® were partnered for further development and commercialization. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

About Magenta Therapeutics

Headquartered in Cambridge, MA, USA, Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.

Contact

Heidelberg Pharma AG
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
Email: [investors\[at\]hdpharma.com](mailto:investors[at]hdpharma.com)
Schriesheimer Str. 101, 68526 Ladenburg

IR/PR support

MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Email: [katja.arnold\[at\]mc-services.eu](mailto:katja.arnold[at]mc-services.eu)

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.